Next generation sequencing guided treatment of ALK tyrosine kinase inhibitor induced long survival in lung squamous cell carcinoma harboring ROS1 gene fusions: a case report and literature review

Approximately 1–2% of non-small cell lung cancer (NSCLC) cases harbor ROS1 gene fusions. However, lung squamous cell carcinoma (LUSC) patients with ROS1 rearrangements remain exceptionally rare. Current targeted therapies for LUSC harboring ALK, ROS1, or EGFR mutations are typically guided by protoc...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mei Liu, Fenge Li, Ning Mu, Ning Kang, Shengnan Wu, Yue Xu, Xinyi Wang, Huan Lü, Chunhua Ma
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-03-01
Serija:	Frontiers in Medicine
Teme:	drug resistance long survival lung squamous cell carcinoma molecular-targeted therapy next-generation sequencing - NGS ROS1 gene fusion
Online dostop:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1771353/full
Oznake:	Označite Brez oznak, prvi označite!